" class="no-js "lang="en-US"> Ensysce Biosciences - Medtech Alert
Monday, September 08, 2025
Ensysce Biosciences | Pharmtech Focus

Ensysce Biosciences

About Ensysce Biosciences

Ensysce Biosciences

Ensysce Biosciences San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.

Related Story

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

September 1 2022

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC) (OTC PINK: ENSCW), a clinical-stage biotech company […]